Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.
You may also be interested in...
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.